Your browser doesn't support javascript.
loading
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Sobral-Leite, Marcelo; Van de Vijver, Koen; Michaut, Magali; van der Linden, Rianne; Hooijer, Gerrit K J; Horlings, Hugo M; Severson, Tesa M; Mulligan, Anna Marie; Weerasooriya, Nayana; Sanders, Joyce; Glas, Annuska M; Wehkamp, Diederik; Mittempergher, Lorenza; Kersten, Kelly; Cimino-Mathews, Ashley; Peters, Dennis; Hooijberg, Erik; Broeks, Annegien; van de Vijver, Marc J; Bernards, Rene; Andrulis, Irene L; Kok, Marleen; de Visser, Karin E; Schmidt, Marjanka K.
Afiliación
  • Sobral-Leite M; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Van de Vijver K; Coordenação de Pesquisa, Instituto Nacional de Câncer, Rio de Janeiro, RJ, Brasil.
  • Michaut M; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Linden R; Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hooijer GKJ; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Horlings HM; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
  • Severson TM; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mulligan AM; Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Weerasooriya N; Laboratory Medicine Program, University Health Network, Toronto, ON, Canada.
  • Sanders J; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Glas AM; University Health Network, Toronto, ON, Canada.
  • Wehkamp D; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mittempergher L; Agendia NV, Science Park, Amsterdam, The Netherlands.
  • Kersten K; Agendia NV, Science Park, Amsterdam, The Netherlands.
  • Cimino-Mathews A; Agendia NV, Science Park, Amsterdam, The Netherlands.
  • Peters D; Division of Tumor Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Hooijberg E; Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA.
  • Broeks A; Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van de Vijver MJ; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bernards R; Core Facility Molecular Pathology and Biobanking, Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Andrulis IL; Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
  • Kok M; Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Visser KE; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Schmidt MK; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.
Oncoimmunology ; 7(12): e1509820, 2018.
Article en En | MEDLINE | ID: mdl-30524905
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos